Abstract: Topical formulations comprising a dipeptide having a sequence of Lys-Pro, optionally complexed with an amino add, and at least one bioflavonoid or bioflavonoid extract in a cosmetically or pharmaceutically acceptable carrier provide intense skin hydration and improve skin texture and appearance.

Abstract: A nanomedicinal composition comprising a nanocarrier and a pharmaceutical agent mixture comprising an anti-cancer therapeutic and an antioxidant. The nanocarrier comprises a porous silicate matrix and particles of a magnetic ferrite disposed in the pores of the porous silicate matrix. The pharmaceutical agent mixture is disposed in the pores and/or on the surface of the nanocarrier by a solution phase impregnation process. The nanomedicinal composition is used in a method of treating breast cancer.

Abstract: Disclosed are compositions and methods for the co-delivery of ribonucleic acids and interferon binding proteins. Compositions include mineral coated microparticles having a mineral layer, a ribonucleic acid, and an interferon binding protein. Ribonucleic acids and interferon binding proteins can be adsorbed to the mineral layer, can be incorporated into the mineral Layer, and combinations thereof. Also disclosed are methods for co-delivery of ribonucleic acids and interferon binding proteins and methods for treating inflammatory diseases using mineral coated microparticles having a mineral layer to provide co-delivery of ribonucleic acids and interferon binding proteins.

Abstract: In various embodiments, the present invention is directed to a degradable poly(ester urea) (PEU)-based adhesion barrier, particularly suitable for use in connection with surgical mesh repair in the treatment of hernias and other soft tissue injuries comprising an amino acid based poly(ester urea) backbone and one or more zwitterionic side chains connected to the amino acid based poly(ester urea) backbone through a sulfide bond. In some other embodiments, the present invention is directed to method of making the PEU-based adhesion barriers comprising: preparing an amino acid based PEU polymer or terpolymer having one or more allyl functional groups; preparing a thiol functionalized zwitterionic compound; and reacting the allyl functionalized PEU polymer or terpolymer with the thiol functionalized zwitterionic compound to form a degradable PEU-based adhesion barrier having an amino acid based PEU backbone having zwitterionic side chains.

Abstract: This invention relates to a cosmetic composition comprising, in a physiologically acceptable medium, at least one microcapsule comprising at least: —a core, —a first laminated coating surrounding said core comprising at least 45% by weight of the total weight, of a microcapsule of multilayer interference particles comprising at least one iron oxide, and —a second laminated coating surrounding said first coating, comprising between 10 and 40% by weight of titanium dioxide relative to the total weight of a microcapsule, said multilayer interference particles being released from said microcapsule(s) only when said composition is applied on a keratin material such as keratin fibers or the skin.

Abstract: Embodiments provide an apparel product. The apparel product includes a major component forming a base portion of the apparel product and is configured to be supported and worn at least partially over a portion of a wearer. The apparel product includes a minor component forming a secondary portion configured to be coupled to the major component. An adhesive is disposed at least partially between a portion of the major component and a portion of the minor component. The adhesive includes a shape memory material.

Abstract: A polymeric material fiber includes a polymeric material which is a homopolymer of caprolactone or a copolymer of at least 90% by weight of caprolactone and one or more additional monomers. An implantable mesh includes this fiber alone or combined with one or more additional fiber materials. Methods for treating patients involve implanting the fiber material, for example incorporated in a mesh.

Abstract: Stable, solid triamine compositions are disclosed. The pressed, cast, extruded or other solid compositions are suitable for antimicrobial, sanitizing and disinfectant applications. Ready-to-use solutions are obtained by dissolving the solid triamine compositions with water and the methods of use thereof are particularly suitable for cleaning, disinfecting, sanitizing, rinsing and/or lubricating. Beneficially, the solid triamine compositions are at least partially neutralized, allowing activity of 90% and greater of the biocidal triamine, and provide at least substantially similar or superior performance and micro efficacy to liquid formulations.

Abstract: Alprazolam formulated as an inhaled condensation aerosol and method for treating epilepsy and/or seizures.

Abstract: Cosmetic compositions capable of forming a multilayer structure after application to a keratinous material are provided, as well as methods of applying such compositions to a keratinous material.

Abstract: The invention relates to a hemostatic composition comprising a mixture of cellulose-based short and long fibers, preparation and use thereof.

Abstract: The present invention relates to a risperidone sustained release delivery system for treatment of medical conditions relating to delusional psychosis, schizophrenia, bipolar disorder, psychotic depression, obsessive-compulsion disorder, Tourette syndrome, and autistic spectrum disorders. The sustained release delivery system includes a flowable composition containing risperidone, a metabolite, or a prodrug thereof and an implant containing risperidone, a metabolite, or a prodrug thereof. The flowable composition may be infected into tissue whereupon it coagulates to become a solid or gel, monolithic implant. The flowable composition includes a biodegradable, thermoplastic polymer, an organic liquid, and risperidone, a metabolite or a prodrug thereof.

Abstract: Lip compositions including at least one semi-crystalline acrylate copolymer, wherein the compositions include at least two components prior to mixing and application to lips and are capable of forming a multilayer structure after application to lips, are provided.

Abstract: A hemostatic composition is provided. The hemostatic composition includes a hemostatically effective amount of a hemostatic agent that includes a nanoparticle and a polyphosphate polymer attached to the nanoparticle. Also provided are medical devices and methods of use to promote blood clotting.

Abstract: A cosmetic gel sheet suitable for a cosmetic field or a medical field is provided. The cosmetic gel sheet of the present invention contains carboxy group-containing water-soluble polymer, polyalcohol, and acid as essential constituent components. Carboxy group-containing polysaccharide can be suitably used as the carboxy group-containing water-soluble polymer. Water content in the gel sheet is 30% by weight, but it is more preferable if the water content is 10% by weight or less. In the cosmetic gel sheet of the present invention, the gel sheet can be manufactured by drying an aqueous solution containing carboxy group-containing water-soluble polymer, polyalcohol, and acid as essential components. Wherein, it is desirable that content of the acid in the aqueous solution is adjusted to a value appropriate for setting pH of the aqueous solution to 2.0-4.0.

Abstract: The present disclosure relates to a solid hair cosmetic composition comprising—based on the total weight of the cosmetic composition—0.1 to 40.0% by weight of at least one polysaccharide, at least one polysaccharide being starch from corn, rice, potato or tapioca; modified starch; hydroxypropyl starch phosphate or a dextrin, and optionally: 10.0 to 60.0% by weight of at least one polyhydric alcohol, 0.1 to 15.0% by weight of at least one cationic surfactant, and 0.1 to 15.0% by weight of at least one saturated or unsaturated, branched or unbranched C8-C30 alcohol and/or a saturated or unsaturated, branched or unbranched C8-C30 carboxylic acid and/or a salt of a saturated or unsaturated, branched or unbranched C8-C30 carboxylic acid, as well as production and application methods and uses thereof.

Abstract: This cosmetic contains: (a) 30 mass % or less of a highly oil-absorbing powder; (b) a volatile oil solution; and (c) a nonvolatile oil solution having a kinematic viscosity at 25° C. of 5 to 100 mm2/s. The mixture mass ratio represented by (a)/(c) is 0.37 to 2.0.

Abstract: Medical articles formed from a polyurethane-based resin including a modifying oligomer provide enhanced properties. A modifying oligomer incorporated into a backbone, as a side chain, or both of the polyurethane-based resin formed by a diisocyanate, a polyglycol, and a diol chain extender has at least one, preferably two, alcohol moieties (C—OH) and a functional moiety. Exemplary modifying oligomers are: a diol-containing perfluoropolyether incorporated into the backbone, a monofunctional polysiloxane (e.g., monodialcohol-terminated polydimethylsiloxane) incorporated as the side chain, and combinations thereof. Medical articles herein are self-lubricating and/or anti-fouling.

Abstract: An implantable medical device is disclosed comprising a thermoplastic composite body having anterior, first lateral, second lateral, posterior, superior, and inferior surfaces, and at least one dense portion and at least one porous portion which are integrally formed. The at least one dense portion is formed of a first thermoplastic polymer matrix that is essentially non-porous, and which is continuous through a thickness dimension from the superior surface to the inferior surface. The at least one porous portion is formed of a porous thermoplastic polymer scaffold having a second thermoplastic polymer matrix which is continuous through the thickness dimension. A method for forming the thermoplastic composite body is disclosed comprising disposing a first powder mixture in a first portion of a mold, disposing a second powder mixture in a second portion of the mold, simultaneously molding the first powder mixture and the second powder mixture, and leaching porogen.

Abstract: An autologous bone graft substitute composition for inducing new bone formation, promoting bone growth and treating bone defects, a method of preparation thereof, and a method of inducing or promoting bone growth by treatment of a bone with an autologous bone graft substitute composition. The composition includes autologous blood; one or more analogs of an osteogenic bone morphogenetic protein selected from BMP-6, BMP-2, BMP-7, BMP-4, BMP-5, BMP-8, BMP-9, BMP-12, and BMP-13, and combinations thereof; and a compression resistant matrix selected from the group consisting of a bone autograft, bone allograft, hydroxyapatite, tri-calcium phosphate, and combinations thereof. The autologous blood forms a coagulum gel comprising a fibrin-meshwork reinforced with the compression resistant matrix and containing the osteogenic bone morphogenetic protein which is released over a sustained period.